Vir Biotechnology Corporate Update and Third Quarter 2026 Financial Results - VIR BIOTECHNOLOGY INC

Explicit Guidance:

• Cash Runway: Projected to fund operations into the second half of 2028 based on current operating plans, excluding the $90 million Gilead upfront payment received in October 2026.
• Financial Flexibility: Management intends to maintain disciplined capital allocation to preserve flexibility around future inflection points.

Business-Segment Outlook:

• Hepatitis Delta (HDV):
  • Data Release Timeline: Top-line data for ECLIPSE-1 expected in Q4 2026; ECLIPSE-2 and ECLIPSE-3 top-line data expected in Q1 2027.
  • Trial Scope: ECLIPSE-1 (treatment-naive), ECLIPSE-2 (switch from bulevirtide), and ECLIPSE-3 (head-to-head vs. bulevirtide) designed to provide a comprehensive regulatory package.
  • Strategic Positioning: Aiming to redefine treatment expectations with a regimen targeting "Target Not Detected" (TND) in ~66% of patients (based on Phase 2 Solstice) compared to competitors' lower rates (~12–20%).
  • Pre-launch Activities: Ongoing market research with HCPs, payer engagement, and distribution channel development for both in-home and provider administration.
• Oncology (VIR-5500 - Prostate Cancer):
  • Regulatory Status: Holds FDA Fast-Track designation for late-line metastatic castration-resistant prostate cancer (mCRPC).
  • Development Plan: Goal to initiate multiple Phase 3 studies spanning early-line and late-line settings in 2027.
  • Partnership: Co-development/commercialization with Astellas, which recently confirmed "proof-of-concept" for the program.
• Oncology (VIR-5818 - HER2):
  • Timeline Adjustments: Study remains ongoing with a refined design to add backfill cohorts in a homogeneous population; meaningful update anticipated at a future scientific conference rather than in the current year.
• Oncology (VIR-5525 - EGFR):
  • Progress: Dose escalation continues across multiple tumor types (lung, colorectal, head and neck, cutaneous).
• Platform Validation: Preclinical collaboration with Gilead announced, leveraging AI-enabled discovery and ProX10 masking technology for next-generation T-cell engagers in solid tumors.

Market and Competitive Outlook:

• HDV Landscape: Anticipates increased testing uptake following the launch of Gilead's Hepcludex, driving diagnosis rates.
• Competitive Bar: Views its monthly subcutaneous dosing regimen as a significant convenience differentiator against daily injections required by bulevirtide; anticipates market need for a switch therapy for patients with inadequate response to bulevirtide.
• Oncology Strategy: Plans to be disciplined in capital allocation, advancing only where capabilities are most differentiated and partnering for breadth.

Macro / Industry Outlook:

• Regulatory Alignment: VIR-5818 study design adjustments are aligned with the FDA's "Project Optimus" initiative to reform dose optimization paradigms.
• Clinical Endpoints: Management confirms FDA agreement on statistical hierarchy: ECLIPSE-1 and -3 focus on TND + ALT normalization (or TND alone) at 48 weeks; ECLIPSE-2 focuses on TND at 24 weeks.

Strategic Initiatives:

• Leadership: Strengthened executive team with the addition of Aziz Sawaf (CFO) and Dr. David Liu (CMO), both with 20+ years of industry experience.
• Gilead Collaboration:
  • Terms: $65 million upfront payment and $25 million equity investment (30% premium); potential for up to $45 million in near-term milestones and $1.74 billion in long-term milestones.
  • Scope: Gilead retains exclusive rights to advance three developed candidates for future development, manufacturing, and commercialization.
  • Financial Impact: Eliminates 20% pass-through economics to Sanofi for this collaboration.
• Investor Communication: Plans to host a virtual research investor event in Q1 2027 to present a comprehensive roadmap for the immuno-oncology franchise.

Risks and Headwinds to Outlook:

• Study Design Refinements: The timeline for VIR-5818 updates may be delayed due to the need to refine study design based on FDA feedback regarding monotherapy dose selection.
• Regulatory Uncertainty: Final success depends on achieving primary endpoints in Phase 3 trials (ECLIPSE-1, -2, -3) and initiating pivotal trials for VIR-5500.
• Competition: Acknowledges competitor data (e.g., Gilead's Hepcludex) influencing the market landscape and payers' expectations, necessitating clear evidence of superiority.
• General Forward-Looking Risks: Standard disclaimer regarding substantial risks and uncertainties that could cause results to differ significantly from expectations.

Management Tone on the Future:

• Confidence: Expresses "incredible pride" in execution and "confidence" in the platform's potential to transform Hepatitis Delta treatment and build a differentiated oncology franchise.
• Positioning: Describes the current period as "pivotal" and the company as entering a phase of "transformative" history with strong financial footing.
• Discipline: Emphasizes "thoughtful and disciplined" capital deployment to maximize long-term shareholder value.

Miscellaneous:

• ECLIPSE Trial Details: ECLIPSE-1 enrolls ~120 treatment-naive patients; ECLIPSE-2 enrolls ~150 switch candidates; ECLIPSE-3 enrolls ~100 head-to-head candidates.
• VIR-5500 Indications: Expansion cohorts covering taxane-naive MCRPC, radioligand therapy-naive and exposed MCRPC, and metastatic hormone-sensitive prostate cancer.